A Role for P-Glycoprotein in Environmental Toxicology
- 7 January 2003
- journal article
- review article
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part B
- Vol. 6 (3) , 279-288
- https://doi.org/10.1080/10937400306466
Abstract
P-Glycoprotein (P-gp) is a transmembrane protein, playing significant roles in the process of drug discovery and development and in pest resistance to pesticides. P-gp affects absorption, disposition, and elimination of different compounds and is mainly expressed in intestines, liver, kidneys, heart, colon, and placenta. The expression of P-gp in the blood-brain barrier (BBB) has been associated with the restricted access of many compounds to the central nervous system. Generated knockout mice by disruption of mdr 1a gene, encoding for P-gp, showed that this protein was expressed in the BBB. The absence or the low levels of P-gp elevated drug concentrations in tissues and decreased drug elimination. P-gp is responsible for resistance of cells to agents, particularly the anticancer drugs, by removing these drugs from cells. Increased expression of P-gp is implicated in decreased HIV drug availability at certain intracellular sites. The role of P-gp in affecting efficacy and toxicity of environmental toxicants such as pesticides and heavy metals has not been adequately investigated. Studies showed that P-gp contributes to resistance to pesticides in certain pest species, and to decrease toxicity by removing compounds from cells in mammals. Placental drug-transporting P-gp plays a significant role in limiting the transport of toxicants such as potential teratogens to the fetus. Several in vitro or in vivo assays, including using P-gp knockout or naturally deficient mice, were described for testing P-gp modulators. The role of P-gp following concurrent exposure to more multiple compounds needs further research. P-gp modulators should be carefully used, since some modulators that reverse P-gp efflux action in vitro may lead to alterations of tissue function and increase toxicity of xenobiotics in normal tissues. Recent reports from the pharmaceutical studies on the significance of P-gp as transporters in altering the efficacy and toxicity clearly highlight the need for further research in interaction with environmental toxicants.Keywords
This publication has 40 references indexed in Scilit:
- Nuclear Receptors and Lipid Physiology: Opening the X-FilesScience, 2001
- Induction of P-glycoprotein expression by HIV protease inhibitors in cell cultureAIDS, 2000
- The Contribution of P‐glycoprotein to Pharmacokinetic Drug‐Drug InteractionsThe Journal of Clinical Pharmacology, 1999
- Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of Haemonchus contortusMolecular and Biochemical Parasitology, 1998
- Reversal of P-glycoprotein-associated multidrug resistance by ivermectinBiochemical Pharmacology, 1997
- Are the Major Effects of P-Glycoprotein Modulators Due to Altered Pharmacokinetics of Anticancer Drugs?Therapeutic Drug Monitoring, 1996
- Functional expression of mouse Mdr1 in an outer membrane permeability mutant of Escherichia coli.Proceedings of the National Academy of Sciences, 1996
- CHLORPYRIFOS OXON INTERACTS WITH THE MAMMALIAN MULTIDRUG RESISTANCE PROTEIN, P-GLYCOPROTEINJournal of Toxicology and Environmental Health, 1996
- Efficacy of the herbicide trifluralin against four P-glycoprotein-expressing strains of LeishmaniaAntimicrobial Agents and Chemotherapy, 1995
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugsPublished by Elsevier ,1994